|
| 36373344 | A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial. | Alzheimers Dement | 2023 |
| 36923965 | The relative contribution of COVID-19 infection versus COVID-19 related occupational stressors to insomnia in healthcare workers. | Sleep Med X | 2023 |
| 36809662 | A randomized controlled clinical trial of prazosin for alcohol use disorder in active duty soldiers: Predictive effects of elevated cardiovascular parameters. | Alcohol Clin Exp Res (Hoboken) | 2023 |
| 35103388 | Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer's disease carriers and non-carriers: Baseline findings from the API ADAD Colombia Trial. | Alzheimers Dement | 2022 |
| 36324797 | The relative contribution of COVID-19 infection versus COVID-19 related occupational stressors to insomnia in healthcare workers. | medRxiv | 2022 |
| 34918181 | The Impact of the COVID-19 Pandemic on Mental Health, Occupational Functioning, and Professional Retention Among Health Care Workers and First Responders. | J Gen Intern Med | 2022 |
| 35124650 | Markers of Cerebrovascular Injury, Inflammation, and Plasma Lipids Are Associated with Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Cognitively Normal Persons. | J Alzheimers Dis | 2022 |
| 34155411 | A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. | Nat Med | 2021 |
| 33614888 | Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia. | Alzheimers Dement (N Y) | 2021 |
| 33586212 | Power and sample size for random coefficient regression models in randomized experiments with monotone missing data. | Biom J | 2021 |
| 34930444 | Impact of potential modifications to Alzheimer's disease clinical trials in response to disruption by COVID-19: a simulation study. | Alzheimers Res Ther | 2021 |
| 34252876 | PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease-causing Presenilin-1 E280A mutation carriers. | Neuroimage Clin | 2021 |
| 32460855 | The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease. | Alzheimers Res Ther | 2020 |
| 34713026 | Optimizing Aggregated N-Of-1 Trial Designs for Predictive Biomarker Validation: Statistical Methods and Theoretical Findings. | Front Digit Health | 2020 |
| 32995469 | Development of a novel cognitive composite outcome to assess therapeutic effects of exercise in the EXERT trial for adults with MCI: The ADAS-Cog-Exec. | Alzheimers Dement (N Y) | 2020 |
| 32418361 | Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial. | Alzheimers Dement | 2020 |
| 30636733 | Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication. | J Alzheimers Dis | 2019 |
| 31492718 | Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial. | Neurology | 2019 |
| 31282954 | Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease: A Phase 2 Randomized Clinical Trial. | JAMA Neurol | 2019 |
| 30872114 | A randomized clinical trial to evaluate home-based assessment of people over 75Â years old. | Alzheimers Dement | 2019 |
| 29582053 | Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial. | JAMA Neurol | 2018 |
| 29955659 | The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical <i>PSEN1</i> E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort. | Alzheimers Dement (N Y) | 2018 |
| 29181489 | The Alzheimer's Prevention Initiative Generation Program: Evaluating CNP520 Efficacy in the Prevention of Alzheimer's Disease. | J Prev Alzheimers Dis | 2017 |
| 28381516 | Randomized controlled trials in mild cognitive impairment: Sources of variability. | Neurology | 2017 |
| 28381506 | A phase 3 trial of IV immunoglobulin for Alzheimer disease. | Neurology | 2017 |
| 26917500 | Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials. | Alzheimers Dement | 2016 |
| 29067300 | Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease. | Alzheimers Dement (N Y) | 2016 |
| 25301682 | Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. | Alzheimers Dement | 2015 |
| 26362286 | A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. | Neurology | 2015 |
| 26064192 | Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's disease. | Alzheimers Res Ther | 2015 |
| 24450890 | Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. | N Engl J Med | 2014 |
| 24886908 | The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. | JAMA Neurol | 2014 |
| 24696507 | Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease. | Neurology | 2014 |
| 24656849 | Estimating long-term multivariate progression from short-term data. | Alzheimers Dement | 2014 |
| 23253777 | Putting the Alzheimer's cognitive test to the test I: traditional psychometric methods. | Alzheimers Dement | 2013 |
| 23883379 | A phase 3 trial of semagacestat for treatment of Alzheimer's disease. | N Engl J Med | 2013 |
| 23876113 | Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. | Neuropsychology | 2013 |
| 24016464 | Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. | Rev Neurol (Paris) | 2013 |
| 23391006 | Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: a new approach. | Alzheimers Dement | 2013 |
| 23253779 | Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory. | Alzheimers Dement | 2013 |
| 22343285 | Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. | Proc Natl Acad Sci U S A | 2012 |
| 22499454 | Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. | J Nutr Health Aging | 2012 |
| 22410444 | Incidence of new-onset seizures in mild to moderate Alzheimer disease. | Arch Neurol | 2012 |
| 22431837 | Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. | Arch Neurol | 2012 |
| 20921876 | Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease. | Alzheimer Dis Assoc Disord | 2011 |
| 21810649 | Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. | Arch Gen Psychiatry | 2011 |
| 21795660 | A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. | Neurology | 2011 |
| 21917762 | Chronic divalproex sodium use and brain atrophy in Alzheimer disease. | Neurology | 2011 |
| 21554992 | The relative efficiency of time-to-threshold and rate of change in longitudinal data. | Contemp Clin Trials | 2011 |
| 21502597 | A phase II trial of huperzine A in mild to moderate Alzheimer disease. | Neurology | 2011 |